Denali 制药

最新新闻

• 评级变动
  BofA Securities Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Announces Target Price $31
  \u5e02\u573a\u8d44\u8baf · 2026/7/15
• B. Riley Securities Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $35
  \u5e02\u573a\u8d44\u8baf · 2026/8/25
• 评级变动
  BTIG Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $39
  \u5e02\u573a\u8d44\u8baf · 2026/5/11
• 评级变动
  Morgan Stanley Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $36
  \u5e02\u573a\u8d44\u8baf · 2026/7/23
• 评级变动
  Morgan Stanley Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $35
  \u5e02\u573a\u8d44\u8baf · 2026/5/26
• 评级变动
  William Blair Maintains Denali Therapeutics(DNLI.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/5/9
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Agilon Health (AGL), CG Oncology, Inc. (CGON) and Denali Therapeutics (DNLI)
  TipRanks · 2026/5/9
• 评级变动
  Baird Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $34
  \u5e02\u573a\u8d44\u8baf · 2026/4/7
• 评级变动
  J.P. Morgan Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $29
  \u5e02\u573a\u8d44\u8baf · 2026/7/13
• 评级变动
  Wedbush Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Cuts Target Price to $23
  \u5e02\u573a\u8d44\u8baf · 2026/5/8
• UBS Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $25
  \u5e02\u573a\u8d44\u8baf · 2026/6/16
• 评级变动
  A Quick Look at Today's Ratings for Denali Therapeutics(DNLI.US), With a Forecast Between $31 to $41
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  Morgan Stanley Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Cuts Target Price to $40
  \u5e02\u573a\u8d44\u8baf · 2026/5/14
• 评级变动
  H.C. Wainwright Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $42
  \u5e02\u573a\u8d44\u8baf · 2026/7/13
• 评级变动
  Deutsche Bank Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $35
  \u5e02\u573a\u8d44\u8baf · 2026/7/16
• Wedbush Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $26
  \u5e02\u573a\u8d44\u8baf · 2026/7/13
• A Quick Look at Today's Ratings for Denali Therapeutics(DNLI.US), With a Forecast Between $31 to $42
  \u5e02\u573a\u8d44\u8baf · 2026/8/8
• J.P. Morgan Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $29
  \u5e02\u573a\u8d44\u8baf · 2026/8/11
• 评级变动
  Oppenheimer Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $40
  \u5e02\u573a\u8d44\u8baf · 2026/5/11
• 评级变动
  TD Cowen Maintains Denali Therapeutics(DNLI.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/5/9

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。